First-ever injectable treatment for HIV prevention approved by FDA
In an announcement on 20 December, the FDA confirmed it has given the green light to the use of Apretude (cabotegravir extended-release injectable suspension) in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds).